La bourse ferme dans 5 h 8 min
  • CAC 40

    5 589,83
    -8,35 (-0,15 %)
     
  • Euro Stoxx 50

    3 530,25
    +2,46 (+0,07 %)
     
  • Dow Jones

    29 910,37
    +37,87 (+0,13 %)
     
  • EUR/USD

    1,1992
    +0,0022 (+0,18 %)
     
  • Gold future

    1 773,00
    -15,10 (-0,84 %)
     
  • BTC-EUR

    15 493,56
    +163,65 (+1,07 %)
     
  • CMC Crypto 200

    365,63
    -4,88 (-1,32 %)
     
  • Pétrole WTI

    44,89
    -0,64 (-1,41 %)
     
  • DAX

    13 385,07
    +49,39 (+0,37 %)
     
  • FTSE 100

    6 380,34
    +12,76 (+0,20 %)
     
  • Nasdaq

    12 205,85
    +350,85 (+2,96 %)
     
  • S&P 500

    3 638,35
    +8,70 (+0,24 %)
     
  • Nikkei 225

    26 433,62
    -211,09 (-0,79 %)
     
  • HANG SENG

    26 341,49
    -553,19 (-2,06 %)
     
  • GBP/USD

    1,3347
    +0,0033 (+0,25 %)
     

Global Fragment-based Drug Discovery Industry

ReportLinker
·19 min de lecture

Global Fragment-based Drug Discovery Market to Reach $1. 1 Billion by 2027. Amid the COVID-19 crisis, the global market for Fragment-based Drug Discovery estimated at US$568 Million in the year 2020, is projected to reach a revised size of US$1.

New York, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Fragment-based Drug Discovery Industry" - https://www.reportlinker.com/p05960939/?utm_source=GNW
1 Billion by 2027, growing at aCAGR of 10.4% over the period 2020-2027. Fragment Screening Technique, one of the segments analyzed in the report, is projected to record 11% CAGR and reach US$644.2 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Fragment Optimization Technique segment is readjusted to a revised 9.7% CAGR for the next 7-year period.

The U.S. Market is Estimated at $168.6 Million, While China is Forecast to Grow at 9.7% CAGR

The Fragment-based Drug Discovery market in the U.S. is estimated at US$168.6 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$195.6 Million by the year 2027 trailing a CAGR of 9.7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 9.7% and 8.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 8.4% CAGR.We bring years of research experience to this 9th edition of our report. The 176-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

Competitors identified in this market include, among others,

  • Astex Pharmaceuticals, Inc.

  • Beactica AB

  • Charles River Laboratories International, Inc.

  • Evotec AG

  • Sygnature Discovery Ltd.




Read the full report: https://www.reportlinker.com/p05960939/?utm_source=GNW

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Global Competitor Market Shares
Fragment-based Drug Discovery Competitor Market Share Scenario
Worldwide (in %): 2019 & 2025
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Fragment-based
Drug Discovery by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027

Table 2: World Historic Review for Fragment-based Drug
Discovery by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019

Table 3: World 15-Year Perspective for Fragment-based Drug
Discovery by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets for Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for Fragment Screening
Technique by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027

Table 5: World Historic Review for Fragment Screening Technique
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 6: World 15-Year Perspective for Fragment Screening
Technique by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World for Years 2012, 2020 & 2027

Table 7: World Current & Future Analysis for Fragment
Optimization Technique by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027

Table 8: World Historic Review for Fragment Optimization
Technique by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019

Table 9: World 15-Year Perspective for Fragment Optimization
Technique by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Biopharmaceutical
Companies by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027

Table 11: World Historic Review for Biopharmaceutical Companies
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 12: World 15-Year Perspective for Biopharmaceutical
Companies by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World for Years 2012, 2020 & 2027

Table 13: World Current & Future Analysis for Contract Research
Organization by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027

Table 14: World Historic Review for Contract Research
Organization by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019

Table 15: World 15-Year Perspective for Contract Research
Organization by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific
and Rest of World for Years 2012, 2020 & 2027

Table 16: World Current & Future Analysis for Academic and
Research Institutions by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027

Table 17: World Historic Review for Academic and Research
Institutions by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019

Table 18: World 15-Year Perspective for Academic and Research
Institutions by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific
and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

GEOGRAPHIC MARKET ANALYSIS

UNITED STATES
Market Facts & Figures
US Fragment-based Drug Discovery Market Share (in %) by
Company: 2019 & 2025
Market Analytics
Table 19: USA Current & Future Analysis for Fragment-based Drug
Discovery by Service Type - Fragment Screening Technique and
Fragment Optimization Technique - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027

Table 20: USA Historic Review for Fragment-based Drug Discovery
by Service Type - Fragment Screening Technique and Fragment
Optimization Technique Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019

Table 21: USA 15-Year Perspective for Fragment-based Drug
Discovery by Service Type - Percentage Breakdown of Value Sales
for Fragment Screening Technique and Fragment Optimization
Technique for the Years 2012, 2020 & 2027

Table 22: USA Current & Future Analysis for Fragment-based Drug
Discovery by End-Use - Biopharmaceutical Companies, Contract
Research Organization and Academic and Research Institutions -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027

Table 23: USA Historic Review for Fragment-based Drug Discovery
by End-Use - Biopharmaceutical Companies, Contract Research
Organization and Academic and Research Institutions Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019

Table 24: USA 15-Year Perspective for Fragment-based Drug
Discovery by End-Use - Percentage Breakdown of Value Sales for
Biopharmaceutical Companies, Contract Research Organization and
Academic and Research Institutions for the Years 2012, 2020 &
2027

CANADA
Table 25: Canada Current & Future Analysis for Fragment-based
Drug Discovery by Service Type - Fragment Screening Technique
and Fragment Optimization Technique - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027

Table 26: Canada Historic Review for Fragment-based Drug
Discovery by Service Type - Fragment Screening Technique and
Fragment Optimization Technique Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 27: Canada 15-Year Perspective for Fragment-based Drug
Discovery by Service Type - Percentage Breakdown of Value Sales
for Fragment Screening Technique and Fragment Optimization
Technique for the Years 2012, 2020 & 2027

Table 28: Canada Current & Future Analysis for Fragment-based
Drug Discovery by End-Use - Biopharmaceutical Companies,
Contract Research Organization and Academic and Research
Institutions - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027

Table 29: Canada Historic Review for Fragment-based Drug
Discovery by End-Use - Biopharmaceutical Companies, Contract
Research Organization and Academic and Research Institutions
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019

Table 30: Canada 15-Year Perspective for Fragment-based Drug
Discovery by End-Use - Percentage Breakdown of Value Sales for
Biopharmaceutical Companies, Contract Research Organization and
Academic and Research Institutions for the Years 2012, 2020 &
2027

JAPAN
Table 31: Japan Current & Future Analysis for Fragment-based
Drug Discovery by Service Type - Fragment Screening Technique
and Fragment Optimization Technique - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027

Table 32: Japan Historic Review for Fragment-based Drug
Discovery by Service Type - Fragment Screening Technique and
Fragment Optimization Technique Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 33: Japan 15-Year Perspective for Fragment-based Drug
Discovery by Service Type - Percentage Breakdown of Value Sales
for Fragment Screening Technique and Fragment Optimization
Technique for the Years 2012, 2020 & 2027

Table 34: Japan Current & Future Analysis for Fragment-based
Drug Discovery by End-Use - Biopharmaceutical Companies,
Contract Research Organization and Academic and Research
Institutions - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027

Table 35: Japan Historic Review for Fragment-based Drug
Discovery by End-Use - Biopharmaceutical Companies, Contract
Research Organization and Academic and Research Institutions
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019

Table 36: Japan 15-Year Perspective for Fragment-based Drug
Discovery by End-Use - Percentage Breakdown of Value Sales for
Biopharmaceutical Companies, Contract Research Organization and
Academic and Research Institutions for the Years 2012, 2020 &
2027

CHINA
Table 37: China Current & Future Analysis for Fragment-based
Drug Discovery by Service Type - Fragment Screening Technique
and Fragment Optimization Technique - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027

Table 38: China Historic Review for Fragment-based Drug
Discovery by Service Type - Fragment Screening Technique and
Fragment Optimization Technique Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 39: China 15-Year Perspective for Fragment-based Drug
Discovery by Service Type - Percentage Breakdown of Value Sales
for Fragment Screening Technique and Fragment Optimization
Technique for the Years 2012, 2020 & 2027

Table 40: China Current & Future Analysis for Fragment-based
Drug Discovery by End-Use - Biopharmaceutical Companies,
Contract Research Organization and Academic and Research
Institutions - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027

Table 41: China Historic Review for Fragment-based Drug
Discovery by End-Use - Biopharmaceutical Companies, Contract
Research Organization and Academic and Research Institutions
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019

Table 42: China 15-Year Perspective for Fragment-based Drug
Discovery by End-Use - Percentage Breakdown of Value Sales for
Biopharmaceutical Companies, Contract Research Organization and
Academic and Research Institutions for the Years 2012, 2020 &
2027

EUROPE
Market Facts & Figures
European Fragment-based Drug Discovery Market: Competitor
Market Share Scenario (in %) for 2019 & 2025
Market Analytics
Table 43: Europe Current & Future Analysis for Fragment-based
Drug Discovery by Geographic Region - France, Germany, Italy,
UK and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2020 through 2027

Table 44: Europe Historic Review for Fragment-based Drug
Discovery by Geographic Region - France, Germany, Italy, UK and
Rest of Europe Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019

Table 45: Europe 15-Year Perspective for Fragment-based Drug
Discovery by Geographic Region - Percentage Breakdown of Value
Sales for France, Germany, Italy, UK and Rest of Europe Markets
for Years 2012, 2020 & 2027

Table 46: Europe Current & Future Analysis for Fragment-based
Drug Discovery by Service Type - Fragment Screening Technique
and Fragment Optimization Technique - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027

Table 47: Europe Historic Review for Fragment-based Drug
Discovery by Service Type - Fragment Screening Technique and
Fragment Optimization Technique Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 48: Europe 15-Year Perspective for Fragment-based Drug
Discovery by Service Type - Percentage Breakdown of Value Sales
for Fragment Screening Technique and Fragment Optimization
Technique for the Years 2012, 2020 & 2027

Table 49: Europe Current & Future Analysis for Fragment-based
Drug Discovery by End-Use - Biopharmaceutical Companies,
Contract Research Organization and Academic and Research
Institutions - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027

Table 50: Europe Historic Review for Fragment-based Drug
Discovery by End-Use - Biopharmaceutical Companies, Contract
Research Organization and Academic and Research Institutions
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019

Table 51: Europe 15-Year Perspective for Fragment-based Drug
Discovery by End-Use - Percentage Breakdown of Value Sales for
Biopharmaceutical Companies, Contract Research Organization and
Academic and Research Institutions for the Years 2012, 2020 &
2027

FRANCE
Table 52: France Current & Future Analysis for Fragment-based
Drug Discovery by Service Type - Fragment Screening Technique
and Fragment Optimization Technique - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027

Table 53: France Historic Review for Fragment-based Drug
Discovery by Service Type - Fragment Screening Technique and
Fragment Optimization Technique Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 54: France 15-Year Perspective for Fragment-based Drug
Discovery by Service Type - Percentage Breakdown of Value Sales
for Fragment Screening Technique and Fragment Optimization
Technique for the Years 2012, 2020 & 2027

Table 55: France Current & Future Analysis for Fragment-based
Drug Discovery by End-Use - Biopharmaceutical Companies,
Contract Research Organization and Academic and Research
Institutions - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027

Table 56: France Historic Review for Fragment-based Drug
Discovery by End-Use - Biopharmaceutical Companies, Contract
Research Organization and Academic and Research Institutions
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019

Table 57: France 15-Year Perspective for Fragment-based Drug
Discovery by End-Use - Percentage Breakdown of Value Sales for
Biopharmaceutical Companies, Contract Research Organization and
Academic and Research Institutions for the Years 2012, 2020 &
2027

GERMANY
Table 58: Germany Current & Future Analysis for Fragment-based
Drug Discovery by Service Type - Fragment Screening Technique
and Fragment Optimization Technique - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027

Table 59: Germany Historic Review for Fragment-based Drug
Discovery by Service Type - Fragment Screening Technique and
Fragment Optimization Technique Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 60: Germany 15-Year Perspective for Fragment-based Drug
Discovery by Service Type - Percentage Breakdown of Value Sales
for Fragment Screening Technique and Fragment Optimization
Technique for the Years 2012, 2020 & 2027

Table 61: Germany Current & Future Analysis for Fragment-based
Drug Discovery by End-Use - Biopharmaceutical Companies,
Contract Research Organization and Academic and Research
Institutions - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027

Table 62: Germany Historic Review for Fragment-based Drug
Discovery by End-Use - Biopharmaceutical Companies, Contract
Research Organization and Academic and Research Institutions
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019

Table 63: Germany 15-Year Perspective for Fragment-based Drug
Discovery by End-Use - Percentage Breakdown of Value Sales for
Biopharmaceutical Companies, Contract Research Organization and
Academic and Research Institutions for the Years 2012, 2020 &
2027

ITALY
Table 64: Italy Current & Future Analysis for Fragment-based
Drug Discovery by Service Type - Fragment Screening Technique
and Fragment Optimization Technique - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027

Table 65: Italy Historic Review for Fragment-based Drug
Discovery by Service Type - Fragment Screening Technique and
Fragment Optimization Technique Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 66: Italy 15-Year Perspective for Fragment-based Drug
Discovery by Service Type - Percentage Breakdown of Value Sales
for Fragment Screening Technique and Fragment Optimization
Technique for the Years 2012, 2020 & 2027

Table 67: Italy Current & Future Analysis for Fragment-based
Drug Discovery by End-Use - Biopharmaceutical Companies,
Contract Research Organization and Academic and Research
Institutions - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027

Table 68: Italy Historic Review for Fragment-based Drug
Discovery by End-Use - Biopharmaceutical Companies, Contract
Research Organization and Academic and Research Institutions
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019

Table 69: Italy 15-Year Perspective for Fragment-based Drug
Discovery by End-Use - Percentage Breakdown of Value Sales for
Biopharmaceutical Companies, Contract Research Organization and
Academic and Research Institutions for the Years 2012, 2020 &
2027

UNITED KINGDOM
Table 70: UK Current & Future Analysis for Fragment-based Drug
Discovery by Service Type - Fragment Screening Technique and
Fragment Optimization Technique - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027

Table 71: UK Historic Review for Fragment-based Drug Discovery
by Service Type - Fragment Screening Technique and Fragment
Optimization Technique Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019

Table 72: UK 15-Year Perspective for Fragment-based Drug
Discovery by Service Type - Percentage Breakdown of Value Sales
for Fragment Screening Technique and Fragment Optimization
Technique for the Years 2012, 2020 & 2027

Table 73: UK Current & Future Analysis for Fragment-based Drug
Discovery by End-Use - Biopharmaceutical Companies, Contract
Research Organization and Academic and Research Institutions -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027

Table 74: UK Historic Review for Fragment-based Drug Discovery
by End-Use - Biopharmaceutical Companies, Contract Research
Organization and Academic and Research Institutions Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019

Table 75: UK 15-Year Perspective for Fragment-based Drug
Discovery by End-Use - Percentage Breakdown of Value Sales for
Biopharmaceutical Companies, Contract Research Organization and
Academic and Research Institutions for the Years 2012, 2020 &
2027

REST OF EUROPE
Table 76: Rest of Europe Current & Future Analysis for
Fragment-based Drug Discovery by Service Type - Fragment
Screening Technique and Fragment Optimization Technique -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027

Table 77: Rest of Europe Historic Review for Fragment-based
Drug Discovery by Service Type - Fragment Screening Technique
and Fragment Optimization Technique Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019

Table 78: Rest of Europe 15-Year Perspective for Fragment-based
Drug Discovery by Service Type - Percentage Breakdown of Value
Sales for Fragment Screening Technique and Fragment
Optimization Technique for the Years 2012, 2020 & 2027

Table 79: Rest of Europe Current & Future Analysis for
Fragment-based Drug Discovery by End-Use - Biopharmaceutical
Companies, Contract Research Organization and Academic and
Research Institutions - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027

Table 80: Rest of Europe Historic Review for Fragment-based
Drug Discovery by End-Use - Biopharmaceutical Companies,
Contract Research Organization and Academic and Research
Institutions Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019

Table 81: Rest of Europe 15-Year Perspective for Fragment-based
Drug Discovery by End-Use - Percentage Breakdown of Value Sales
for Biopharmaceutical Companies, Contract Research Organization
and Academic and Research Institutions for the Years 2012, 2020 &
2027

ASIA-PACIFIC
Table 82: Asia-Pacific Current & Future Analysis for
Fragment-based Drug Discovery by Service Type - Fragment
Screening Technique and Fragment Optimization Technique -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027

Table 83: Asia-Pacific Historic Review for Fragment-based Drug
Discovery by Service Type - Fragment Screening Technique and
Fragment Optimization Technique Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 84: Asia-Pacific 15-Year Perspective for Fragment-based
Drug Discovery by Service Type - Percentage Breakdown of Value
Sales for Fragment Screening Technique and Fragment
Optimization Technique for the Years 2012, 2020 & 2027

Table 85: Asia-Pacific Current & Future Analysis for
Fragment-based Drug Discovery by End-Use - Biopharmaceutical
Companies, Contract Research Organization and Academic and
Research Institutions - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027

Table 86: Asia-Pacific Historic Review for Fragment-based Drug
Discovery by End-Use - Biopharmaceutical Companies, Contract
Research Organization and Academic and Research Institutions
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019

Table 87: Asia-Pacific 15-Year Perspective for Fragment-based
Drug Discovery by End-Use - Percentage Breakdown of Value Sales
for Biopharmaceutical Companies, Contract Research Organization
and Academic and Research Institutions for the Years 2012, 2020 &
2027

REST OF WORLD
Table 88: Rest of World Current & Future Analysis for
Fragment-based Drug Discovery by Service Type - Fragment
Screening Technique and Fragment Optimization Technique -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027

Table 89: Rest of World Historic Review for Fragment-based Drug
Discovery by Service Type - Fragment Screening Technique and
Fragment Optimization Technique Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019

Table 90: Rest of World 15-Year Perspective for Fragment-based
Drug Discovery by Service Type - Percentage Breakdown of Value
Sales for Fragment Screening Technique and Fragment
Optimization Technique for the Years 2012, 2020 & 2027

Table 91: Rest of World Current & Future Analysis for
Fragment-based Drug Discovery by End-Use - Biopharmaceutical
Companies, Contract Research Organization and Academic and
Research Institutions - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027

Table 92: Rest of World Historic Review for Fragment-based Drug
Discovery by End-Use - Biopharmaceutical Companies, Contract
Research Organization and Academic and Research Institutions
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019

Table 93: Rest of World 15-Year Perspective for Fragment-based
Drug Discovery by End-Use - Percentage Breakdown of Value Sales
for Biopharmaceutical Companies, Contract Research Organization
and Academic and Research Institutions for the Years 2012, 2020 &
2027

IV. COMPETITION
Total Companies Profiled: 44
Read the full report: https://www.reportlinker.com/p05960939/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001